← SynDRA
DROSPIRENONE
SynDRA canonical compound SYN0008337 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PGR |
|---|
| Mechanism of action | Mineralocorticoid receptor antagonist |
|---|
| Indication | contraceptive |
|---|
| Disease area | endocrinology |
|---|
All known targets
Mechanisms of action (all sources)
- Mineralocorticoid receptor antagonist
- NR3C2 ANTAGONIST
- PGR AGONIST
- NR3C2 BINDER
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NR3C1
- ABCB11
- NPY1R
- HRH2
- HRH3
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- MAOA
- MC3R
- MLNR
- NR1I2
- HDAC6
- OPRD1
- OPRK1
- OPRM1
- PDE3A
- PDE4D
- PTGS2
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- TBXA2R
- HRH1
- GHSR
- ABCC2
- ESR1
- ABCC4
- ADORA1
- ADORA2A
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACM1
- ANDR
- CP2CJ
- CP3A4
- CP3A7
- ESRRA
- GCR
- GLI3
- IFNG
- KSYK
- RARA
- SYK
Drug classes
- Diuretics
- Hormone Antagonists
- Mineralocorticoid Receptor Antagonists
- Natriuretic Agents
- Progestin
ATC classes
- G03A · HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
- PROGESTOGENS AND ESTROGENS IN COMBINATION
Cross-references
Synonyms
- ANGELIQ
- BEYAZ
- DROSPIRENONE AND ESTRADIOL
- DROSPIRENONE AND ETHINYL ESTRADIOL
- DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM
- KEMEYA
- KYRA
- LO-ZUMANDIMINE
- LORYNA
- MELAMISA
- NEXTSTELLIS
- dihydrospirorenone
- drospirenona
- Drospirenona
- NSC-760103
- ZK-30595
- Drospirenone component of angeliq
- Drospirenone component of beyaz
- Drospirenone component of nextstellis
- Drospirenone component of safyral
- Drospirenone component of yasmin
- Drospirenone component of yaz
- Slynd
- DRSP
- Dehydrospirorenone
- Dihydrospirorenone
- Drospirenonum
- Drospirenone [INN]
- ZK30595
- Angeliq, Drospirenone
- Drospirenona [INN-Spanish]
- Drospirenonum [INN-Latin]
- SH-470
- Drospirenone (JAN/USAN/INN)
- 1,2-Dihydrospirorenone
- 1,2-dihydro-spirorenone
- CHEBI:50838
Reported adverse events
- Cancer
- Dementia
- DVT
- Breast cancer
- Cardiovascular disorder
- TIA
- Headache
- Depression
- Hypersensitivity
- Acne
- Nausea
- Chloasma
Look up DROSPIRENONE in the interactive SynDRA portal →